Processa Pharmaceuticals Inc PCSA

US Pharmaceuticals

$2.15 ▲ +5.39% (+$0.11)

🎈 Low Float 📅 Earnings This Week

Open $2.00

Prev Close $2.04

Day Range $1.92 – $2.20

52W Range $1.67 – $14.24

Market Cap $5.95M

Beta 1.01

EPS (TTM) $-10.90

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-10-07
Shares Out.	3,350,000
Website	processapharmaceuticals.com/ ↗
Phone	13026587581
Employees	12
Net Income	-$3.4M
Total Assets	$4.5M
Total Liabilities	$2.0M
Equity	$2.5M

About Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Processa Pharmaceuticals Inc is a publicly traded company under the ticker symbol PCSA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.